AzTrials
AzTrials

Prevention of White Spot LesionsNCT05127889

the Remineralizing Self-Assembling Peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride White Spot Lesions

A study testing curodont in people with Prevention of White Spot Lesions, run by Ain Shams University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the current study is to compare the remineralizing ability of Self-assembling peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride varnishes in treatment of white spot lesions both in-vivo and in-vitro . Read more about this study

Who is it for?
Ages 8 to 12 years
Conditions the study is for
Prevention of White Spot Lesions
What is being tested?
curodont
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
39 participants
Where
No sites listed yet
Study dates
1 Jan 2022to 1 Jan 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Patients aged from 8 to 12 years old
  • Patients who are medically free from any diseases that would cause enamel defects.
  • Patients should have WSLs in labial surface of upper or lower permanent anterior teeth with a score of 1 \& 2 according to the ICDAS that don't require operative intervention.

Who cannot join

  • Patients receiving the following medications will be excluded from the study: tetracyclines, any other medication known to stain teeth, any medication causing dry mouth and/or xerostomia.
  • Uncooperative patients
  • Mouth breathers

Trial locations and contacts

No sites are listed yet.

About this study

Official title: Comparative Evaluation of the Remineralizing Ability of Self-Assembling Peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride Varnishes in Treatment of White Spot Lesions (Randomized Clinical Trial and In Vitro Study)

The aim of the current study is to compare the remineralizing ability of Self-assembling peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride varnishes in treatment of white spot lesions both in-vivo and in-vitro .

  1. Primary Objective

Assessment of:

  • Dimensions of the WSLs through digital photography.
  • The color of WSLs through spectrophotometer. B) Secondary Objectives

Assessment of:

  • Degree of remineralization using Polarized Light Microscope.
Read the detailed description

White spot lesions (WSLs), defined as "white opacity," occur as a result of subsurface enamel demineralization that is located on smooth surfaces of teeth. The reason of the white appearance is the changes in light-scattering optical properties of the decalcified enamel. The aim of the current study is to compare the remineralizing ability of Self-assembling peptide P11-4, 2% Arginine Enriched Sodium Fluoride and Functionalized Tri Calcium Phosphate Fluoride varnishes

  1. Primary Objective

Assessment of:

  • Dimensions of the WSLs through digital photography.
  • The color of WSLs through spectrophotometer. B) Secondary Objectives

Assessment of:

  • Degree of remineralization using Polarized Light Microscope.

PICOTS:

  • P - Participants: Children in the age group of 8-12 years having early demineralized carious lesions (WSLs).
  • I - Intervention: -Self-assembling peptide P11-4 varnish
  • Arginine enriched Sodium Fluoride varnish C- Comparison:- Functionalized Tri Calcium Phosphate Fluoride varnish
  • O -Outcomes:- Reduction in WSLs dimensions and color improvement.
  • Reduction in degree of demineralization of WSLs.
  • T- Time: study period will be over 9 months.
  • S- Study design: Randomized Controlled Trial (RCT) and in vitro study

This study will consist of two parts: in vivo part (RCT) and in vitro part:

  1. In vivo part:
  • Study design: Randomized controlled trial (RCT)
  • Grouping: Patients will be randomly allocated into one of the three groups (13/each): Group 1: Self-assembling peptide P11-4 varnish (study group) Group 2: Arginine-enriched Sodium Fluoride varnish (study group) Group 3: Tri Calcium Phosphate Fluoride varnish (positive control group) Materials used in the study:
  • Self-assembling-peptide (P11-4)
  • Fluoride varnish with TCP5%
  • L-Arginine Sodium Fluoride Varnish
  • Clinical procedures: All interventions will be performed by the primary investigator as follows:
  • The dental plaque deposit has to be removed before the assessment. Dental prophylaxis will be performed with a bristle brush and non-fluoridated prophylactic paste during the initial clinical examination and before any examination.
  • photographic assessment by digital camera and color change( E) readings by digital spectrophotometer ( VITA Easy shade) will be performed at 0 , 3 months, 6 months and 9 months throughout the study period for all the patients.
  • During the photographic assessment, all the photographs will be taken with digital camera, Macro lens configuration will be used, the image quality will be set as fine and ISO sensitivity 200. All images will be saved as Joint Photographic Experts Group (JPEG) files suitable for manipulation with the image analysis software.
  • Patient's confidentiality will be respected through the photographic technique.
  • After digital images captured, they will be downloaded and stored as JPEG. Then the images will be analyzed, and compared with baseline images by Abode Photoshop and Auto CAD
  • The enamel color of each WSL will be measured using the spectrophotometer.
  • All measurements will be performed under standardized ambient conditions to ensure accuracy and reproducibility.
  • Three images will be randomly captured for each lesion and analyzed. Group 1 (Self assembling peptide P11-4) Prior to application of the test material the following will be done:
  • Test lesions will be wiped with NaOCl to remove pellicle,
  • Etched for 20 s with 35% H3PO4 Etching Gel to remove mineral deposits on the tooth surface and rinsed with water in accordance with the manufacturer's instructions.
  • The lesions will be dried and isolated with cotton rolls.
  • The varnish will be applied and left undisturbed for 5minutes (till disappearance) to allow diffusion of self-assembly. Group 2 (Arginine Enriched Sodium fluoride group) Preparation and application of the varnish as following:
  • The Arginine powder will be suspended at 2%.
  • A 10 mL of 5% sodium fluoride varnish tube dispensed in a sterile container.
  • 200 mg of Arginine will be vigorously mixed with the varnish matrix for 60 sec using a sterile microbrush.
  • After dryness of the white spot lesion, the prepared varnish will be applied evenly using the micro brush.
  • After application the patient will be instructed to avoid rinsing, eating soft diet and avoid hot drinks for 2 hrs. Group 3 (Tri Calcium Phosphate fluoride) the material will be applied according to the manufacturing instructions as following:
  • To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.
  • The varnish will be mixed with the brush to avoid separation of the material during storage
  • However, to guarantee the best results suction will be used during application of the varnish.
  • A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush
  • The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.
  • After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs. All patients will be encouraged to maintain good oral hygiene through regular brushing. Follow up Patients will be recalled for further applications after 3 and 6 months (20) and for WSLs assessment after 3, 6, 9 months. Outcome measurement: Photographic assessment and color change reading outcomes will be assessed by two other blinded calibrated examiners at the following periods:
  1. Baseline 2. 3-month evaluation 3. 6-month evaluation 4. 9-month evaluation

Photographic assessment:

The following will be determined, from photographs for all the patients in relation to WSLs:

  1. The area of the labial surface of the tooth
  2. WSL area
  3. The area of WSL to area of the labial surface of the tooth ratio percent (Percent of WSL)
  4. The percentage of WSL ratio related to initial condition at the measured time (Relative Percent)
  5. The percentage of decrease in WSL ratio due to time (Percent Decrease)
  6. The decrease in the WSL area related to the initial condition (Relative Decrease) Color change readings
  • The values of L* (differences in lightness munsell system ranging from O (black) to 100 (white)), a* (green-red coordinate), and b* (blue yellow coordinate) will be recorded for the WSL and the adjacent sound enamel.
  • Color change, will be calculated as the color difference between the treated and untreated enamel.
  • Participant timeline The study interventions are expected to be conducted from 2021 until 2023.
Being tested
curodont
Keywords
Wsls,

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • curodontDrug

    • To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.
    • The varnish will be mixed with the brush to avoid separation of the material during storage
    • However, to guarantee the best results suction will be used during application of the varnish.
    • A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush
    • The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.
    • After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.
Study groups in NCT05127889
Study groupRoleWhat they receive
Self-assembling peptide P11-4 varnish (study group)Experimental* Test lesions will be wiped with NaOCl to remove pellicle, * Etched for 20 s with 35% H3PO4 Etching Gel to remove mineral deposits on the tooth surface and rinsed with water in accordance with the manufacturer's instructions. * The lesions will be dried and isolated with cotton rolls. * The varnish will be applied and left undisturbed for 5minutes (till disappearance) to allow diffusion of self-assembly.
Receives: Drug: curodont
Arginine-enriched Sodium Fluoride varnish (study group)Experimental* The Arginine powder will be suspended at 2%. * A 10 mL of 5% sodium fluoride varnish tube dispensed in a sterile container. * 200 mg of Arginine will be vigorously mixed with the varnish matrix for 60 sec using a sterile microbrush. * After dryness of the white spot lesion, the prepared varnish will be applied evenly using the micro brush. * After application the patient will be instructed to avoid rinsing, eating soft diet and avoid hot drinks for 2 hrs.
Receives: Drug: curodont
Tri Calcium Phosphate Fluoride varnish (positive control group)Active comparator* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide. * The varnish will be mixed with the brush to avoid separation of the material during storage * However, to guarantee the best results suction will be used during application of the varnish. * A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush * The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles. * After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs. All patients will be encouraged to maintain good oral hygiene through regular brushing.
Receives: Drug: curodont

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. dimensional and color assessment

    Photographic assessment and color change reading outcomes will be assessed by two other blinded calibrated examiners

    Measured: 1. Baseline 2. 3-month evaluation 3. 6-month evaluation 4. 9-month evaluation

Secondary outcomes (1)
  1. Evaluation of the remineralizing ability and degree of remineralization of each agent

    Polarized Light Microscopy (PLM) will used for evaluation.

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2021
  2. Study start1 Jan 2022 (estimated)
  3. Primary completion2 Apr 2023 (estimated)
  4. Study completion1 Jan 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
assignment
Masking
Single blind
Who is masked
Participant
Enrolment
39 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05127889
Sponsor's protocol ID
PED21-3D
Status last verified
Nov 2021
First submitted
9 Nov 2021
Last updated
19 Nov 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing curodont in people with Prevention of White Spot Lesions, run by Ain Shams University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact bardis salah (01000239043, paradise19899@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

dimensional and color assessment (time frame: 1. Baseline 2. 3-month evaluation 3. 6-month evaluation 4. 9-month evaluation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in